Eyepoint Pharmaceuticals, Inc. (NASDAQ:EYPT) Receives Average Recommendation of "Moderate Buy" from Brokerages

Key Points

• Eyepoint Pharmaceuticals has a “Moderate Buy” consensus rating from nine analysts: seven Buy, one Strong Buy, and one Sell. The average 12-month price target is $44.38, with individual targets ranging from $37 to $68.
• Institutional ownership is very high at 99.41%. Several major investment firms recently initiated or increased positions, including Janus Henderson, Commodore Capital, Paradigm Biocapital, OrbiMed, and Suvretta Capital.
• Financial losses remain a key risk. The company reported a quarterly loss of $1.09 per share versus the $1.01 consensus estimate, and analysts expect a full-year loss of $3.45 per share despite slightly better-than-expected revenue.

Shares of Eyepoint Pharmaceuticals, Inc. (NASDAQ:EYPT - Get Free Report) have been given an average rating of "Moderate Buy" by the nine brokerages that are currently covering the firm, MarketBeat reports. One investment analyst has rated the stock with a sell recommendation, seven have issued a buy recommendation and one has issued a strong buy recommendation on the company. The average 1-year price target among brokers that have covered the stock in the last year is $44.3750.

A number of research analysts have issued reports on EYPT shares. Guggenheim restated a "buy" rating and issued a $68.00 target price on shares of Eyepoint Pharmaceuticals in a report on Wednesday, June 24th. Cantor Fitzgerald lifted their price target on shares of Eyepoint Pharmaceuticals from $47.00 to $55.00 and gave the stock an "overweight" rating in a report on Thursday. Royal Bank Of Canada cut their price objective on shares of Eyepoint Pharmaceuticals from $39.00 to $37.00 and set an "outperform" rating for the company in a research report on Thursday, May 7th. Chardan Capital reaffirmed a "buy" rating and issued a $65.00 target price on shares of Eyepoint Pharmaceuticals in a research note on Friday. Finally, Stifel Nicolaus initiated coverage on Eyepoint Pharmaceuticals in a report on Thursday, July 16th. They set a "buy" rating and a $40.00 price objective on the stock.

Institutional Investors Weigh In On Eyepoint Pharmaceuticals

Institutional investors have recently bought and sold shares of the stock. Janus Henderson Group PLC purchased a new stake in shares of Eyepoint Pharmaceuticals during the 4th quarter valued at $53,658,000. Commodore Capital LP acquired a new stake in shares of Eyepoint Pharmaceuticals during the 1st quarter worth $36,414,000. Paradigm Biocapital Advisors LP acquired a new stake in shares of Eyepoint Pharmaceuticals during the 3rd quarter worth $28,556,000. Orbimed Advisors LLC purchased a new position in shares of Eyepoint Pharmaceuticals in the 3rd quarter worth $25,575,000. Finally, Suvretta Capital Management LLC raised its position in shares of Eyepoint Pharmaceuticals by 26.4% in the 4th quarter. Suvretta Capital Management LLC now owns 7,827,685 shares of the company's stock worth $143,012,000 after buying an additional 1,634,970 shares during the period. 99.41% of the stock is currently owned by hedge funds and other institutional investors.

More Eyepoint Pharmaceuticals News

Here are the key news stories impacting Eyepoint Pharmaceuticals this week:

• Positive Sentiment: RBC Capital maintained its Buy rating on EyePoint Pharmaceuticals, supporting the bullish view of the company’s long-term prospects. RBC Capital Keeps Their Buy Rating on EyePoint Pharmaceuticals
• Positive Sentiment: One analyst price target was raised to $55, implying substantial upside from the stock’s recent trading level and reinforcing expectations that EyePoint’s development pipeline could create significant value. Eyepoint Pharmaceuticals Price Target Raised to $55.00
• Positive Sentiment: A review of EyePoint’s Phase 3 trial design argued that its approach could strengthen the durability profile of its lead programs. Longer-lasting treatments could improve commercial differentiation and the potential market opportunity if clinical results are successful. EyePoint Phase 3 Design Creates a More Valuable Durability Story
• Neutral Sentiment: HC Wainwright retained its Buy rating but kept a $27 price target, indicating continued confidence in EyePoint’s long-term potential despite near-term financial pressure.
• Negative Sentiment: HC Wainwright lowered its price target to $27 from a higher prior level and reduced EPS forecasts across 2026 and 2027. Its FY2026 loss estimate moved to $3.15 per share from $2.69, while FY2027 loss expectations widened to $1.84 from $1.74. The revisions point to higher anticipated expenses or slower progress toward profitability. HC Wainwright Cuts EyePoint Pharmaceuticals Price Target
• Negative Sentiment: The company’s latest quarterly results also showed ongoing losses: EyePoint reported a $1.09 per-share loss, wider than the $1.01 consensus estimate, although revenue slightly exceeded expectations. Continued cash use and substantial operating losses remain key risks for investors.

Eyepoint Pharmaceuticals Price Performance

NASDAQ EYPT opened at $13.89 on Monday. Eyepoint Pharmaceuticals has a fifty-two week low of $9.65 and a fifty-two week high of $19.11. The business has a fifty day moving average of $13.11 and a 200-day moving average of $13.77. The stock has a market cap of $1.20 billion, a price-to-earnings ratio of -3.71 and a beta of 1.76.

Eyepoint Pharmaceuticals (NASDAQ:EYPT - Get Free Report) last posted its quarterly earnings data on Wednesday, August 5th. The company reported ($1.09) EPS for the quarter, missing analysts' consensus estimates of ($1.01) by ($0.08). Eyepoint Pharmaceuticals had a negative return on equity of 135.81% and a negative net margin of 10,994.73%.The company had revenue of $0.51 million for the quarter, compared to analysts' expectations of $0.45 million. As a group, analysts anticipate that Eyepoint Pharmaceuticals will post -3.45 EPS for the current year.

Eyepoint Pharmaceuticals Company Profile

Eyepoint Pharmaceuticals, Inc is a biopharmaceutical company focused on the development and commercialization of therapies for the treatment of ocular diseases. The company's proprietary platform centers on sustained-release formulations designed to improve drug delivery to the posterior segment of the eye, addressing conditions that often require repeated intravitreal injections or intensive topical regimens. Eyepoint's commercial strategy combines in-house sales and marketing capabilities with targeted partnerships to bring its therapies to ophthalmologists and retina specialists across the United States.

Eyepoint's lead products include YUTIQ, a fluocinolone acetonide intravitreal implant indicated for the prevention of relapse in non-infectious uveitis affecting the posterior segment of the eye, and DEXYCU, a dexamethasone intraocular suspension approved for postoperative inflammation following ocular surgery.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source